A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel

Trial Profile

A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Ocular inflammation; Ocular pain
  • Focus Therapeutic Use
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 29 Aug 2017 Status changed from recruiting to completed.
    • 25 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
    • 25 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 15 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top